Core Viewpoint - A securities class action lawsuit has been filed against James Hardie Industries plc for failing to disclose material information during the Class Period, leading to significant financial losses for investors [3][4]. Group 1: Lawsuit Details - Investors have until December 23, 2025, to file lead plaintiff applications in the lawsuit against James Hardie, which is pending in the United States District Court for the Northern District of Illinois [1][2]. - The lawsuit alleges that James Hardie and certain executives violated federal securities laws by not disclosing a 12% decline in sales in the North America Fiber Cement segment, which was attributed to customer destocking [3]. - Following the disclosure of the sales decline, James Hardie's share price dropped over 34%, from $28.43 on August 18, 2025, to $18.64 on August 20, 2025, resulting in a loss of $9.79 per share [4]. Group 2: Company Background - Kahn Swick & Foti, LLC (KSF) is a prominent boutique securities litigation law firm, recognized among the top 10 firms nationally based on total settlement value [5]. - KSF represents a diverse range of clients, including institutional and retail investors, in seeking recoveries for investment losses due to corporate fraud or malfeasance [5].

Core Viewpoint - The Schall Law Firm is investigating Live Oak Bancshares, Inc. for potential violations of securities laws, focusing on misleading statements and undisclosed information that may have affected investors [1][2]. Summary by Sections Investigation Details - The investigation centers on whether Live Oak issued false or misleading statements and failed to disclose critical information to investors [2]. - On November 12, 2025, Live Oak announced it would amend its 2024 Annual Report and Quarterly Reports for the periods ending March 31, 2025, and June 30, 2025, to restate its Consolidated Financial Statements due to errors in cash flow classifications [2]. - The company identified a misclassification of cash flows between operating and investing activities related to loan participations, concluding that the misclassifications were material [2]. Market Reaction - Following the announcement of the investigation and the need for restatements, shares of Live Oak Bancshares experienced a decline [2].

Core Viewpoint - Firefly Aerospace is facing a class action lawsuit due to alleged securities fraud related to its initial public offering and subsequent financial disclosures, which may have misled investors about the company's growth prospects and operational readiness [3][4][5]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Firefly securities from August 7, 2025, to September 29, 2025, alleging that the offering documents contained misleading statements and omitted necessary facts [3]. - Allegations include overstated demand for Firefly's Spacecraft Solutions and the operational readiness of its Alpha rocket program [3]. Group 2: Financial Performance - Firefly conducted its IPO on August 7, 2025, selling 19.296 million shares at $45.00 each [4]. - In its first earnings report as a public company on September 22, 2025, Firefly reported a loss of $80.3 million, or $5.78 per share, compared to a loss of $58.7 million, or $4.60 per share, in the same quarter of 2024 [5]. - Revenue for the second quarter of 2025 was $15.55 million, below analyst estimates of $17.25 million and down 26.2% year-over-year, with the Spacecraft Solutions segment revenue declining by 49% year-over-year to $9.2 million [5]. Group 3: Stock Price Impact - Following the earnings report, Firefly's stock price fell by $7.58, or approximately 15.3%, from $49.52 to $41.94 per share [5]. - After the disclosure of a failed rocket stage on September 29, 2025, shares dropped by $7.64, or about 20.7%, from $36.96 to $29.32 per share [6].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Gauzy Ltd. following the company's announcement of delayed financial results due to insolvency proceedings for its subsidiaries in France [1][2]. Group 1: Company Announcement - On November 14, 2025, Gauzy announced it would not release its third-quarter financial results as planned, citing a court-ordered commencement of insolvency proceedings for three subsidiaries in France [2]. - The stock price of Gauzy fell by $1.35 per share, or 33.58%, closing at $2.67 per share on the same day [2]. Group 2: Legal Investigation - Pomerantz LLP is conducting an investigation on behalf of investors of Gauzy to determine if the company and its officers engaged in securities fraud or other unlawful business practices [1].

Core Viewpoint - Anavex Life Sciences Corp. is under investigation for potential securities fraud and unlawful business practices following a negative trend vote on its Marketing Authorisation Application for blarcamesine, leading to a significant drop in stock price [1][2]. Group 1: Company Overview - Anavex Life Sciences Corp. (NASDAQ: AVXL) is facing scrutiny from Pomerantz LLP regarding possible securities fraud or other unlawful business practices [1]. - The company announced a negative trend vote from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) concerning its drug blarcamesine [2]. Group 2: Market Reaction - Following the announcement of the negative trend vote, Anavex's stock price decreased by $2.05 per share, representing a decline of 35.94%, closing at $3.65 per share on November 14, 2025 [2].

Core Viewpoint - The Perrigo Company plc is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding the acquisition and performance of its infant formula business [1][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled French v. Perrigo Company plc and covers securities purchased between February 27, 2023, and November 4, 2025, with a deadline of January 16, 2026, for potential lead plaintiffs to come forward [1]. - The lawsuit alleges that Perrigo's acquisition of Nestlé's Gateway infant formula plant for $170 million was plagued by significant underinvestment and operational deficiencies [3][4]. - Specific allegations include the need for substantial capital expenditures beyond initial estimates, significant manufacturing deficiencies, and overstated financial results [4]. Group 2: Financial Impact and Stock Performance - On February 27, 2024, Perrigo disclosed acquisition-related charges of $35 million to $45 million for remediation efforts, leading to a 50% decline in earnings per share compared to the previous year [5]. - Following a report on May 7, 2024, net sales dropped to $91 million, a decrease of 34.5%, attributed to lower shipments during remediation efforts, causing a nearly 10% drop in stock price [6]. - On August 6, 2025, Perrigo reported a $30 million decrease in adjusted gross profit, a 6.9% decline, and a gross margin drop to 34.4%, resulting in an over 11% decline in stock price [7]. - On November 5, 2025, Perrigo announced a strategic review of its infant formula business, slashing its fiscal year 2025 outlook, which led to a more than 25% drop in stock price [8].

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. to recover losses incurred by shareholders due to alleged securities fraud between February 23, 2022, and July 30, 2025 [2][4]. Group 1: Lawsuit Details - The lawsuit alleges that Baxter's Novum LVP product had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [3]. - It is claimed that Baxter was aware of multiple device malfunctions, injuries, and deaths related to these defects [3]. - Baxter's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [3]. - The lawsuit suggests that there was an increased risk of customers being instructed to take Novum LVPs out of service and that Baxter would halt all new sales of these pumps [3]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were allegedly materially false and misleading [3]. Group 2: Next Steps for Affected Shareholders - Shareholders who suffered losses during the specified timeframe are encouraged to learn about their rights to seek recovery, with no cost or obligation to participate [4]. Group 3: Legal Representation - Levi & Korsinsky LLP is highlighted as a nationally-recognized securities litigation firm with a strong track record in securing recoveries for shareholders [5]. - The firm has been ranked among the top securities litigation firms in the United States for seven consecutive years [5].

New York, New York--(Newsfile Corp. - November 18, 2025) - If you suffered a loss on your CarMax, Inc. (NYSE: KMX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/carmax-inc-lawsuit-submission-form?prid=178005&wire=5&utm_campaign=1or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.THE LAWSUIT: A class ...

New York, New York--(Newsfile Corp. - November 18, 2025) - If you suffered a loss on your Freeport-McMoRan Inc. (NYSE: FCX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/freeport-mcmoran-inc-lawsuit-submission-form?prid=178004&wire=5&utm_campaign=11or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates. ...

Securities Lawsuit Alert: Primo Brands Corporation / Primo Water Corporation (PRMB) Investors - Contact Levi & Korsinsky Before January 12, 2026November 18, 2025 4:19 PM EST | Source: Levi & Korsinsky, LLPNew York, New York--(Newsfile Corp. - November 18, 2025) - If you suffered a loss on your Primo Brands Corporation / Primo Water Corporation (NYSE: PRMB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https ...